logo

EULAR 2014

June 12, 2014


TREATING PATIENTS NOT DISEASES:
The new challenge of personalised healthcare


Symposium BIOIBERICA
Thursday June 12, 08:15h-09:45h. Room Passy

Program:

Welcome and introduction
Ingrid Möller, MD, PhD (Barcelona, Spain)

Osteoarthritis: a case for personalizad health care?
Virginia Byers kraus, MD, PhD (Durham, North Carolina, US)



Genetic polymorphisms can predict knee OA progression. Results from the Arthrotest® multicenter association study
Ingrid Möller, MD, PhD (Barcelona, Spain)



Development and validation of a genetic model for fracture prediction in post-menopausal women. Results from European cohort study
Serge Ferrari, MD (Geneva, Switzerland)



Biochemical markers to monitor the effects of drugs in knee OA patients
Yves Henrotin, PhD (Liege, Belgium)



Question and answer session



Concluding Remarks
Virginia Byers Kraus, MD, PhD (Durham, North Carolina, US)
Ingrid Möller, MD, PhD (Barcelona, Spain)



An international, double-blind, randomized trial versus celecoxib

Symposium BIOIBERICA
Friday, June 13, 08:15h-09:45h. Room Passy

Program:

Welcome and introduction
Francisco J. Blanco, MD, PhD (A Coruña, Spain)



MOVES rationale, protocol and study design
Pascal Richette, MD, MSc, PhD (Paris, France)



Effects of combined chondroitin sulfate and glucosamine vs celecoxib in patients with moderate-to-severe knee OA pain
Jean-Pierre Pelletier, MD (Montreal, Quebec, Canada)



Safety considerations from MOVES trial
Marc C. Hochberg, MD, MPH (Baltimore, MD, United States)



Impact of meniscal extrusion on the progression of knee OA structural changes: Data from the Osteoarthritis Initiative Progression Cohort
Johanne Martel-Pelletier, PhD (Montreal, Quebec, Canada)



Question and Answer Session



Concluding Remarks
Philip Conaghan, MB BS, PhD, FRACP, FRCP (Leeds, UK)
Francisco J. Blanco, MD, PhD (A Coruña, Spain)

Any doubt?
Contact us and we will write
you as soon as posible.

Contact